On or around 03/12/2019 (Notice of voluntarily dismissal)
Filing Date: January 09, 2019
According to the Complaint, Edge Therapeutics, Inc. ("Edge" or the "Company") is a clinical-stage biotechnology company that seeks to discover, develop, and commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening conditions.
This action stems from a proposed transaction announced on November 26, 2018 (the “Proposed Transaction”), pursuant to which Edge will be acquired by PDS Biotechnology Corporation.
On December 21, 2018, Defendants filed a Form S-4 Registration Statement (the “Registration Statement”) with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.
This case was voluntarily dismissed on March 12, 2019.
Company & Securities Information
Defendant: Edge Therapeutics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: EDGE
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Adam Franchi, et al. v. Edge Therapeutics, Inc., et al.